Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$558M |
| 2 |
Apple
AAPL
|
+$265M |
| 3 |
Microsoft
MSFT
|
+$209M |
| 4 |
Amazon
AMZN
|
+$197M |
| 5 |
Visa
V
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COHR
Coherent Inc
COHR
|
+$86.3M |
| 2 |
TSMC
TSM
|
+$77.2M |
| 3 |
iShares MBS ETF
MBB
|
+$44.5M |
| 4 |
KSU
Kansas City Southern
KSU
|
+$43.8M |
| 5 |
Vale
VALE
|
+$28.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.97% |
| 2 | Financials | 12.67% |
| 3 | Consumer Discretionary | 11.32% |
| 4 | Healthcare | 10.27% |
| 5 | Communication Services | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Broadcom
AVGO
$2T
| $1.43M | ﹤0.01% |
30,040
-630
| -2% | -$29.2K |
|
502
Anika Therapeutics
ANIK
$264M
| $1.42M | ﹤0.01% |
32,861
-290
| -0.9% | -$12.4K |
|
503
Texas Pacific Land
TPL
$27.5B
| $1.42M | ﹤0.01% |
8,001
-36
| -0.4% | -$6.27K |
|
504
Marriott International
MAR
$89.7B
| $1.42M | ﹤0.01% |
10,364
-1,612
| -13% | -$232K |
|
|
LHCG
505
DELISTED
LHC Group LLC
LHCG
| $1.4M | ﹤0.01% |
6,996
-5,525
| -44% | -$1.11M |
|
506
iShares Global Financials ETF
IXG
$687M
| $1.37M | ﹤0.01% |
17,611
+165
| +0.9% | +$12.9K |
|
507
iShares US Pharmaceuticals ETF
IHE
$1.62B
| $1.35M | ﹤0.01% |
21,843
-4,365
| -17% | -$265K |
|
|
ONC
508
BeOne Medicines Ltd
ONC
$33.6B
| $1.35M | ﹤0.01% |
3,934
+2,318
| +143% | +$768K |
|
509
Ironwood Pharmaceuticals
IRWD
$721M
| $1.32M | ﹤0.01% |
102,624
+21,106
| +26% | +$242K |
|
510
PNC Financial Services
PNC
$102B
| $1.32M | ﹤0.01% |
6,926
-660
| -9% | -$124K |
|
|
FRLG
511
DELISTED
Large Cap Growth Index-Linked Exchange Traded Notes due 2028
FRLG
| $1.32M | ﹤0.01% |
4,425
-573
| -11% | -$155K |
|
512
Manitowoc
MTW
$519M
| $1.3M | ﹤0.01% |
+52,896
| New | +$1.26M |
|
513
iShares MSCI ACWI ETF
ACWI
$33.4B
| $1.28M | ﹤0.01% |
12,691
-158
| -1% | -$15.7K |
|
514
Northern Trust
NTRS
$33.5B
| $1.27M | ﹤0.01% |
10,992
-1,211
| -10% | -$139K |
|
515
iShares MSCI Switzerland ETF
EWL
$2.21B
| $1.25M | ﹤0.01% |
25,640
-654
| -2% | -$31.2K |
|
516
Xtrackers USD High Yield Corporate Bond ETF
HYLB
$3.48B
| $1.24M | ﹤0.01% |
30,842
-163,212
| -84% | -$6.54M |
|
517
Pacific Biosciences
PACB
$450M
| $1.24M | ﹤0.01% |
35,412
-23,244
| -40% | -$676K |
|
518
Lantheus
LNTH
$6.58B
| $1.24M | ﹤0.01% |
44,670
-1,594
| -3% | -$36.6K |
|
519
Parker-Hannifin
PH
$126B
| $1.22M | ﹤0.01% |
3,969
-301
| -7% | -$93.2K |
|
520
iShares S&P 100 ETF
OEF
$20.5B
| $1.21M | ﹤0.01% |
6,165
-2,397
| -28% | -$455K |
|
521
Clorox
CLX
$12.6B
| $1.19M | ﹤0.01% |
6,639
-1,374
| -17% | -$251K |
|
522
NIO
NIO
$12B
| $1.19M | ﹤0.01% |
+22,289
| New | +$893K |
|
|
ESTE
523
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $1.11M | ﹤0.01% |
+99,865
| New | +$907K |
|
524
Labcorp
LH
$25.2B
| $1.1M | ﹤0.01% |
4,648
-197
| -4% | -$44.9K |
|
|
FIHD
525
DELISTED
UBS AG FI Enhanced Global High Yield ETN
FIHD
| $1.1M | ﹤0.01% |
4,905
-1,380
| -22% | -$309K |
|
Similar funds
Ken Fisher's Q2 2021 Portfolio in Review
As of Q2 2021, Ken Fisher held 1,100 positions worth $159B, up 12% from $142B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Ken Fisher deployed $4.92B of net new capital in Q2 2021, opening 101 new positions and adding to 388 existing holdings. Its largest new stake was Organon & Co: 967,460 shares worth $29.3M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was TSMC, an estimated $77.2M trimmed.
- Ken Fisher's largest Q2 2021 buy was Organon & Co: 967,460 shares worth $29.3M.
- Ken Fisher added most to Vanguard Intermediate-Term Corporate Bond ETF in Q2 2021, an estimated $558M increase.
- Ken Fisher's biggest Q2 2021 reduction was TSMC, cutting an estimated $77.2M.
- Ken Fisher fully exited Coherent Inc in Q2 2021, selling an estimated $86.3M.
- Ken Fisher's ten largest holdings make up 32% of its $159B portfolio in Q2 2021.
- Ken Fisher opened 101 new positions and closed 90 in Q2 2021.
- Ken Fisher's portfolio value rose 12% quarter-over-quarter to $159B.
Based on Fisher Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.